The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain, while reducing the effects ...

Stocks traded mostly lower on Friday after President Donald Trump followed through on his pledge to enact tariffs on Mexico ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...

The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental There’s a new way for doctors to treat the ...